US20040010134A1
(en)
|
2000-04-12 |
2004-01-15 |
Rosen Craig A. |
Albumin fusion proteins
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
HU229108B1
(en)
*
|
2000-06-16 |
2013-09-30 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7427665B2
(en)
|
2000-12-08 |
2008-09-23 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
EP1351984A2
(en)
*
|
2000-12-13 |
2003-10-15 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
EP2275117B1
(en)
|
2001-07-31 |
2016-10-26 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
HUP0501192A3
(en)
*
|
2001-08-23 |
2006-06-28 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
HUP0700151A2
(en)
*
|
2001-10-18 |
2007-05-29 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
DK1463751T3
(da)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albuminfusionsproteiner.
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
AU2003200839B2
(en)
*
|
2002-01-08 |
2008-12-11 |
Eli Lilly And Company |
Extended glucagon-like peptide-1 analogs
|
US20030191056A1
(en)
*
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
DE60331226D1
(de)
|
2002-05-24 |
2010-03-25 |
Medtronic Inc |
Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
WO2004002417A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
CN1713920A
(zh)
*
|
2002-08-30 |
2005-12-28 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白融合蛋白
|
EP1569682A2
(en)
*
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7314859B2
(en)
|
2002-12-27 |
2008-01-01 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
JP3974619B2
(ja)
*
|
2003-01-10 |
2007-09-12 |
株式会社新潟ティーエルオー |
遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法
|
WO2004069862A1
(ja)
*
|
2003-02-06 |
2004-08-19 |
Keio University |
ペプチド結合体
|
MXPA05009940A
(es)
*
|
2003-03-19 |
2005-12-05 |
Lilly Co Eli |
Compuestos de glp-1 de enlace de glicol polietilenico.
|
KR101198346B1
(ko)
|
2003-04-08 |
2012-11-06 |
노보 노르디스크 에이/에스 |
크로마토그래피 고정상의 재생
|
WO2004089985A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
ATE549028T1
(de)
|
2003-05-15 |
2012-03-15 |
Tufts College |
Stabile analoga von glp-1
|
DK1641483T3
(da)
*
|
2003-06-12 |
2008-06-02 |
Lilly Co Eli |
Fusionsproteiner
|
EA008831B1
(ru)
*
|
2003-06-12 |
2007-08-31 |
Эли Лилли Энд Компани |
Слитые белки аналогов glp-1
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
EP2932981B1
(en)
*
|
2003-09-19 |
2021-06-16 |
Novo Nordisk A/S |
Albumin-binding derivatives of GLP-1
|
US20090238838A1
(en)
*
|
2003-11-13 |
2009-09-24 |
Hanmi Pharm. Ind. Co. Ltd. |
Insulinotropic peptide conjugate using an immunoglobulin fc
|
US8263084B2
(en)
*
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
ES2372495T3
(es)
|
2003-11-13 |
2012-01-20 |
Hanmi Holdings Co., Ltd |
Método para la producción en masa de la región constante de inmunoglobulina.
|
KR101135244B1
(ko)
*
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
DK1687019T3
(en)
|
2003-11-20 |
2018-02-12 |
Novo Nordisk As |
Propylene glycol peptide formulations that are optimal for production and use in injection devices
|
JP4865565B2
(ja)
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
CA2550050A1
(en)
*
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
US20060252693A1
(en)
*
|
2004-01-29 |
2006-11-09 |
Wolfgang Glaesner |
Glucagon-like peptide-1 analogs
|
CN1980687B
(zh)
*
|
2004-02-09 |
2015-05-13 |
人类基因科学公司 |
清蛋白融合蛋白
|
EP1729795B1
(en)
*
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
KR20120034237A
(ko)
*
|
2004-02-11 |
2012-04-10 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성을 갖는 하이브리드 폴리펩티드
|
US8076288B2
(en)
*
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
MXPA06011425A
(es)
*
|
2004-03-31 |
2007-03-12 |
Johnson & Johnson |
Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
SI3404102T1
(sl)
|
2004-04-21 |
2021-11-30 |
Alexion Pharmaceuticals, Inc. |
Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
|
SI1751184T1
(sl)
*
|
2004-05-13 |
2010-01-29 |
Lilly Co Eli |
Fgf-21 fuzijski proteini
|
WO2005120492A1
(en)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
WO2006037811A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
JP5185624B2
(ja)
*
|
2004-12-02 |
2013-04-17 |
ドマンティス リミテッド |
血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
|
EP2168982A1
(en)
*
|
2004-12-22 |
2010-03-31 |
Eli Lilly & Company |
GLP-1 analog fusion protein formulations
|
EP1843788A4
(en)
*
|
2004-12-22 |
2009-11-18 |
Centocor Ortho Biotech Inc |
GLP-1 AGONISTS, COMPOSITIONS, PROCESSES AND USES
|
US20090016959A1
(en)
*
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
KR20070120112A
(ko)
|
2005-03-18 |
2007-12-21 |
노보 노르디스크 에이/에스 |
연장형 glp-1 화합물
|
CN101389346A
(zh)
*
|
2005-03-28 |
2009-03-18 |
森托科尔公司 |
人glp-1模拟体、组合物、方法和用途
|
PT2650020T
(pt)
*
|
2005-05-06 |
2016-12-12 |
Providence Health & Services - Oregon |
Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
|
AU2006247734B2
(en)
*
|
2005-05-13 |
2011-06-23 |
Eli Lilly And Company |
GLP-1 pegylated compounds
|
US8658174B2
(en)
|
2005-07-27 |
2014-02-25 |
Qinghua Wang |
GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
|
US20090175795A1
(en)
*
|
2005-07-29 |
2009-07-09 |
Amprotein Corporation |
Chimeric therapeutic agents
|
EP1924293A4
(en)
*
|
2005-08-06 |
2008-12-24 |
Qinghua Wang |
COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
|
MX2008002028A
(es)
*
|
2005-08-11 |
2008-03-27 |
Amylin Pharmaceuticals Inc |
Polipeptidos hibridos con propiedades de seleccion.
|
EP2330124B1
(en)
*
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
DK1767545T3
(da)
*
|
2005-09-22 |
2010-03-15 |
Biocompatibles Uk Ltd |
GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
|
WO2007049695A1
(ja)
*
|
2005-10-26 |
2007-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
凝集性glp-1アナログおよび徐放性医薬組成物
|
LT1965823T
(lt)
*
|
2005-11-04 |
2016-10-10 |
Glaxosmithkline Llc |
Hipoglikeminių agentų skyrimo būdai
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
CN1962695B
(zh)
*
|
2005-11-09 |
2011-08-31 |
浙江德清安平生物制药有限公司 |
类胰高血素肽-1融合蛋白及其制备和用途
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
EP1961764B1
(en)
*
|
2005-11-30 |
2011-05-11 |
Shionogi Co., Ltd. |
Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
WO2007073486A2
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
DK2463305T3
(en)
*
|
2006-01-12 |
2016-08-29 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and uses thereof
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
WO2007092252A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
EP1816201A1
(en)
*
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
CN101003574B
(zh)
*
|
2006-02-21 |
2010-12-15 |
大连帝恩生物工程有限公司 |
长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用
|
ES2495741T3
(es)
|
2006-04-20 |
2014-09-17 |
Amgen, Inc |
Compuestos de GLP-1
|
EP1854455B1
(en)
|
2006-05-10 |
2009-10-07 |
Biocompatibles UK Limited |
Spherical microcapsules comprising GLP-1 peptides, their production and use
|
EP2636680A3
(en)
|
2006-05-26 |
2013-12-11 |
Amylin Pharmaceuticals, LLC |
Composition and methods for treatment of congestive heart failure
|
CA2654055A1
(en)
|
2006-06-07 |
2007-12-21 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
MX2009000748A
(es)
|
2006-07-18 |
2009-03-31 |
Centocor Inc |
Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
ATE524493T1
(de)
*
|
2006-07-24 |
2011-09-15 |
Biorexis Pharmaceutical Corp |
Exendin-fusionsproteine
|
MX2009001691A
(es)
|
2006-08-31 |
2009-02-25 |
Hoffmann La Roche |
Metodo para produccion del factor de crecimiento i tipo insulina.
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
CN103230598A
(zh)
*
|
2006-09-06 |
2013-08-07 |
费斯生物制药公司 |
融合肽治疗组合物
|
JO2945B1
(en)
*
|
2006-09-13 |
2016-03-15 |
سميث كلاين بيتشام كوربوريشن |
Methods of giving prolonged hypoglycemic agents
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
EP1975176A1
(en)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Novel glp-1 fusion peptides, their production and use
|
WO2008131242A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
CN105688191A
(zh)
|
2007-04-23 |
2016-06-22 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
US8986684B2
(en)
|
2007-07-25 |
2015-03-24 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
WO2009020802A2
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
ES2672770T3
(es)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
CN101842109B
(zh)
|
2007-09-05 |
2014-01-29 |
诺沃-诺迪斯克有限公司 |
用a-b-c-d-衍生的肽和它们的治疗用途
|
JP2010538049A
(ja)
*
|
2007-09-05 |
2010-12-09 |
ノボ・ノルデイスク・エー/エス |
切断型glp−1誘導体及びその治療的使用
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
US20090181037A1
(en)
*
|
2007-11-02 |
2009-07-16 |
George Heavner |
Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
|
MX2010010776A
(es)
|
2008-03-31 |
2010-10-26 |
Glaxo Group Ltd |
Fusiones y conjugados de farmaco.
|
BRPI0911266A2
(pt)
*
|
2008-04-03 |
2015-09-29 |
Hoffmann La Roche |
ensaio de fator de crescimento similar à insulina peguilado
|
CN101328221B
(zh)
*
|
2008-04-14 |
2011-03-23 |
中国药科大学 |
一种降糖多肽融合蛋白及其衍生物的结构及用途
|
EP2307038A4
(en)
|
2008-06-27 |
2013-03-27 |
Univ Duke |
THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
|
JP5563572B2
(ja)
|
2008-07-23 |
2014-07-30 |
ハンミ サイエンス カンパニー リミテッド |
三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
|
US8865868B2
(en)
|
2008-08-06 |
2014-10-21 |
Novo Nordisk Healthcare Ag |
Conjugated proteins with prolonged in vivo efficacy
|
US20100075897A1
(en)
*
|
2008-09-23 |
2010-03-25 |
Jinan University |
Method for sustainedly releasing bioactive peptides and application thereof
|
RU2011118056A
(ru)
|
2008-10-15 |
2012-11-27 |
Ангиокем Инк. |
Конъюгаты агонистов glp-1 и их применение
|
CA2745524C
(en)
|
2008-12-05 |
2020-06-09 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
CN102307897B
(zh)
|
2008-12-05 |
2016-01-20 |
葛兰素集团有限公司 |
选出蛋白酶抗性多肽的方法
|
PT2373681T
(pt)
|
2008-12-10 |
2017-04-11 |
Glaxosmithkline Llc |
Composições farmacêuticas de albiglutida
|
RU2539797C2
(ru)
|
2009-01-22 |
2015-01-27 |
Ново Нордиск Хелс Кеа Аг |
Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
|
CN106986933A
(zh)
|
2009-02-11 |
2017-07-28 |
阿尔布梅迪克斯医疗公司 |
白蛋白变体和缀合物
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
MA33221B1
(fr)
|
2009-03-27 |
2012-04-02 |
Glaxo Group Ltd |
Fusions de médicament et conjugués afférents
|
CN102510759A
(zh)
|
2009-04-20 |
2012-06-20 |
安吉奥开米公司 |
利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌
|
JP5932642B2
(ja)
|
2009-07-02 |
2016-06-08 |
アンジオケム インコーポレーテッド |
多量体ペプチドコンジュゲートおよびその使用
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
EP2461831B1
(en)
|
2009-08-06 |
2018-11-21 |
Novo Nordisk Health Care AG |
Growth hormones with prolonged in-vivo efficacy
|
ES2870914T3
(es)
*
|
2009-08-14 |
2021-10-28 |
Phasebio Pharmaceuticals Inc |
Péptidos intestinales vasoactivos modificados
|
CN101993485B
(zh)
*
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
CN101993496B
(zh)
*
|
2009-08-20 |
2013-06-05 |
重庆富进生物医药有限公司 |
双重调节血糖血脂融合蛋白及其制法和用途
|
EA201290123A1
(ru)
|
2009-09-30 |
2012-10-30 |
Глаксо Груп Лимитед |
Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
|
KR101229610B1
(ko)
*
|
2009-10-09 |
2013-02-05 |
한남대학교 산학협력단 |
Glp-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
|
CN102725312B
(zh)
*
|
2009-10-20 |
2014-10-01 |
佐治亚州立大学研究基金会公司 |
用于糖尿病治疗和β细胞成像的蛋白药物
|
RU2607374C2
(ru)
|
2009-10-30 |
2017-01-10 |
Новозаймс Байофарма Дк А/С |
Варианты альбумина
|
CN102070717B
(zh)
*
|
2009-11-19 |
2013-04-10 |
东莞太力生物工程有限公司 |
融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物
|
EP2509616A4
(en)
|
2009-12-08 |
2013-05-29 |
Teva Pharma |
BCHE-ALBUMIN FUSION PROTEINS FOR THE TREATMENT OF COCAINOMANIA
|
US9695226B2
(en)
|
2010-01-22 |
2017-07-04 |
Novo Nordisk Healthcare Ag |
Growth hormones with prolonged in-vivo efficacy
|
US9211342B2
(en)
|
2010-01-22 |
2015-12-15 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds resistant to proteolytic degradation
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US9981017B2
(en)
|
2010-04-02 |
2018-05-29 |
Hanmi Science Co., Ltd. |
Insulin conjugate using an immunoglobulin fragment
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
CN101875700B
(zh)
*
|
2010-04-09 |
2012-09-26 |
无锡和邦生物科技有限公司 |
一种增加促胰岛素分泌肽融合蛋白生物活性的方法
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
RU2012151296A
(ru)
|
2010-04-30 |
2014-06-10 |
Санва Кагаку Кенкюсо Ко., Лтд |
Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
WO2011153642A1
(en)
*
|
2010-06-10 |
2011-12-15 |
Angiochem Inc. |
Leptin and leptin analog conjugates and fusion proteins and uses thereof
|
CN101891823B
(zh)
*
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
WO2011162830A2
(en)
*
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
AU2011274229A1
(en)
|
2010-07-02 |
2013-01-10 |
Angiochem Inc. |
Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
|
CN102311501A
(zh)
*
|
2010-07-08 |
2012-01-11 |
天津药物研究院 |
含有glp-1或其类似物的融合蛋白、制备方法及其应用
|
CN101906158B
(zh)
*
|
2010-07-14 |
2013-10-23 |
中国药科大学 |
一种聚乙二醇化降糖多肽及其制法和用途
|
KR101382593B1
(ko)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
|
CN102532323B
(zh)
*
|
2010-12-09 |
2014-07-23 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
CN102533655A
(zh)
*
|
2010-12-21 |
2012-07-04 |
青岛黄海制药有限责任公司 |
高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
|
WO2012088608A1
(en)
*
|
2010-12-27 |
2012-07-05 |
Enobia Canada Limited Partnership |
Compositions comprising natriuretic peptides and methods of use thereof
|
AU2012205301B2
(en)
|
2011-01-14 |
2017-01-05 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
KR101969526B1
(ko)
|
2011-02-28 |
2019-04-17 |
고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 |
악성 종양 전이 억제용 의약
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
MY161450A
(en)
|
2011-04-12 |
2017-04-14 |
Novo Nordisk As |
Double-acylated glp-1 derivatives
|
CA2873553C
(en)
|
2011-06-06 |
2020-01-28 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
JP2014523900A
(ja)
|
2011-06-28 |
2014-09-18 |
インヒブルクス リミティド ライアビリティ カンパニー |
セルピン融合ポリペプチド及びその使用方法
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
AU2012275295B2
(en)
|
2011-06-28 |
2016-11-10 |
Inhibrx, Lp |
WAP domain fusion polypeptides and methods of use thereof
|
EP2726502A1
(en)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Relaxin fusion polypeptides and uses thereof
|
AU2012283235A1
(en)
|
2011-07-08 |
2014-01-09 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing Relaxin and uses thereof
|
WO2013027680A1
(ja)
|
2011-08-19 |
2013-02-28 |
独立行政法人国立循環器病研究センター |
ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
|
JP6118251B2
(ja)
*
|
2011-08-25 |
2017-04-19 |
株式会社Lsiメディエンス |
グルカゴン様ペプチド−1の測定方法及びそれに使用するキット
|
CN104039822A
(zh)
|
2011-09-06 |
2014-09-10 |
诺沃—诺迪斯克有限公司 |
Glp-1衍生物
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
US20150038417A1
(en)
|
2011-12-09 |
2015-02-05 |
Novo Nordisk A/S |
GLP-1 Agonists
|
KR101895047B1
(ko)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
AR090281A1
(es)
|
2012-03-08 |
2014-10-29 |
Hanmi Science Co Ltd |
Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
|
CA2861592A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
RS57727B1
(sr)
|
2012-03-22 |
2018-12-31 |
Novo Nordisk As |
Kompozicije glp-1 peptida i njihovo dobijanje
|
WO2013157002A1
(en)
|
2012-04-19 |
2013-10-24 |
Prolor Biotech Inc. |
Long-acting oxyntomodulin variants and methods of producing same
|
WO2013171570A1
(en)
|
2012-05-16 |
2013-11-21 |
Glaxo Group Limited |
Polypeptide loaded poca nanoparticles for oral administration
|
AU2013263349B2
(en)
|
2012-05-17 |
2016-09-08 |
Extend Biosciences, Inc |
Carriers for improved drug delivery
|
CN107739409A
(zh)
*
|
2012-05-18 |
2018-02-27 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
CA2869674A1
(en)
|
2012-06-08 |
2013-12-12 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
IN2015DN01115A
(pl)
|
2012-07-13 |
2015-06-26 |
Zymeworks Inc |
|
AR094821A1
(es)
*
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
AR092862A1
(es)
*
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
WO2014072481A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
KR102202255B1
(ko)
|
2012-11-20 |
2021-01-13 |
옵코 바이오로직스 리미티드 |
생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
KR20150096433A
(ko)
|
2012-12-21 |
2015-08-24 |
사노피 |
이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
|
CA2896793A1
(en)
|
2013-01-15 |
2014-07-24 |
Teva Pharmaceutical Industries Ltd. |
Formulations of albu-bche, preparation and uses thereof
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
CN104277112B
(zh)
*
|
2013-07-04 |
2018-01-26 |
嘉和生物药业有限公司 |
长效降血糖融合蛋白
|
KR102376451B1
(ko)
|
2013-07-31 |
2022-03-23 |
암젠 인크 |
성장 분화 인자 15(gdf-15) 작제물
|
CN103408669B
(zh)
*
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
Glp-1类似物融合蛋白,及其制备方法和用途
|
CN104371019B
(zh)
|
2013-08-13 |
2019-09-10 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
|
EP3033355A1
(en)
*
|
2013-08-16 |
2016-06-22 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
EP3054973B1
(en)
|
2013-10-10 |
2020-12-02 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
JP2017501970A
(ja)
*
|
2013-12-10 |
2017-01-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
AU2015242657B2
(en)
*
|
2014-03-31 |
2020-05-21 |
Hanmi Pharm. Co., Ltd. |
Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
NO2776305T3
(pl)
|
2014-04-23 |
2018-01-27 |
|
|
ES2818824T3
(es)
|
2014-05-08 |
2021-04-14 |
Phasebio Pharmaceuticals Inc |
Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
CN104558198A
(zh)
*
|
2014-07-25 |
2015-04-29 |
成都贝爱特生物科技有限公司 |
GLP-1类似物和amylin类似物的融合蛋白制备及其用途
|
CN104257696B
(zh)
*
|
2014-09-04 |
2017-08-25 |
西安国誉生物科技有限公司 |
一种降糖稳糖酵母菌粉及其制备方法和应用
|
WO2016034186A1
(en)
|
2014-09-05 |
2016-03-10 |
University Of Copenhagen |
Gip peptide analogues
|
CN107108713A
(zh)
*
|
2014-10-10 |
2017-08-29 |
诺和诺德股份有限公司 |
稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
|
CN104327187B
(zh)
*
|
2014-10-11 |
2018-06-08 |
上海兴迪金生物技术有限公司 |
一种重组人GLP-1-Fc融合蛋白
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
WO2016065042A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
WO2016073704A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
MX2017007392A
(es)
|
2014-12-05 |
2019-01-24 |
Alexion Pharma Inc |
Tratamiento de convulsiones con fosfatasa alcalina recombinante.
|
CA2968987C
(en)
*
|
2014-12-08 |
2022-05-10 |
1Globe Biomedical Co., Ltd. |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
EP3250227A2
(en)
|
2015-01-28 |
2017-12-06 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
ES2822598T3
(es)
|
2015-02-09 |
2021-05-04 |
Phasebio Pharmaceuticals Inc |
Métodos y composiciones para tratar enfermedades y trastornos musculares
|
CA2975633A1
(en)
|
2015-02-11 |
2016-08-18 |
Gmax Biopharm Llc. |
Stable pharmaceutical solution formulation of glp-1r antibody fusion protein
|
JP2018511329A
(ja)
*
|
2015-04-01 |
2018-04-26 |
ザ スクリプス リサーチ インスティテュート |
Gpcrアゴニストポリペプチドに関連する方法および組成物
|
TN2017000432A1
(en)
|
2015-04-10 |
2019-04-12 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
AR105616A1
(es)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
JP6823055B2
(ja)
|
2015-06-15 |
2021-01-27 |
アンジオケム インコーポレーテッド |
軟髄膜癌腫症の治療方法
|
ES2893616T3
(es)
|
2015-06-19 |
2022-02-09 |
Opko Biologics Ltd |
Factores de coagulación de acción prolongada y métodos para la producción de los mismos
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
RU2745528C2
(ru)
|
2015-08-17 |
2021-03-26 |
Алексион Фармасьютикалз, Инк. |
Производство щелочных фосфатаз
|
EP3337816B1
(en)
|
2015-08-20 |
2024-02-14 |
Albumedix Ltd |
Albumin variants and conjugates
|
AU2016315889A1
(en)
|
2015-09-04 |
2018-03-22 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
US11229686B2
(en)
|
2015-09-28 |
2022-01-25 |
Alexion Pharmaceuticals, Inc. |
Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
|
JP2018533571A
(ja)
|
2015-10-30 |
2018-11-15 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
患者の頭蓋縫合早期癒合症を治療するための方法
|
CN105367664B
(zh)
*
|
2015-11-04 |
2019-09-20 |
成都贝爱特生物科技有限公司 |
激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
|
EP3967707A1
(en)
*
|
2015-11-16 |
2022-03-16 |
Ubiprotein, Corp. |
A method for extending half-life of a protein
|
EP3925969A1
(en)
|
2015-11-24 |
2021-12-22 |
Transfert Plus, S.E.C. |
Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
RU2754558C2
(ru)
|
2016-04-01 |
2021-09-03 |
Алексион Фармасьютикалз, Инк. |
Лечение мышечной слабости с помощью щелочных фосфатаз
|
EP3436020A4
(en)
|
2016-04-01 |
2019-12-25 |
Alexion Pharmaceuticals, Inc. |
METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
|
CN109071634A
(zh)
|
2016-04-26 |
2018-12-21 |
R.P.谢勒技术有限责任公司 |
抗体偶联物及其制备和使用方法
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
SG10202100189WA
(en)
|
2016-07-11 |
2021-02-25 |
Opko Biologics Ltd |
Long-acting coagulation factor vii and methods of producing same
|
CN106046176B
(zh)
*
|
2016-08-16 |
2019-09-10 |
中国药科大学 |
一种高活性长效降糖融合蛋白及其制备方法与医药用途
|
JP7018933B2
(ja)
|
2016-08-18 |
2022-02-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
気管気管支軟化症の治療方法
|
CN106279400A
(zh)
*
|
2016-09-06 |
2017-01-04 |
中国药科大学 |
P8降糖肽的设计及其用途
|
WO2018045872A1
(zh)
*
|
2016-09-06 |
2018-03-15 |
中国药科大学 |
一种多肽及其用途
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
CN110582302A
(zh)
*
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和/或蛋白有效负载递送的组合物和方法
|
CN106519016A
(zh)
*
|
2016-12-20 |
2017-03-22 |
中国药科大学 |
降糖调脂肽——Progly肽的设计及其用途
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
EP3574004A1
(en)
*
|
2017-01-25 |
2019-12-04 |
Medimmune, LLC |
Relaxin fusion polypeptides and uses thereof
|
KR20190129058A
(ko)
|
2017-03-31 |
2019-11-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
|
CN108727486A
(zh)
*
|
2017-04-24 |
2018-11-02 |
舒泰神(北京)生物制药股份有限公司 |
长效神经生长因子、制备方法及其组合物
|
AU2018273406A1
(en)
|
2017-05-24 |
2020-01-16 |
Transfert Plus, S.E.C. |
Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
|
JP2020521784A
(ja)
|
2017-05-31 |
2020-07-27 |
ユニバーシティ オブ コペンハーゲン |
長時間作用性gipペプチド類似体
|
PL3474820T3
(pl)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Kompozycje glp-1 i ich zastosowania
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
EP3713593A2
(en)
|
2017-11-21 |
2020-09-30 |
Eli Lilly and Company |
Methods of using and compositions containing dulaglutide
|
CN115109166A
(zh)
*
|
2017-11-24 |
2022-09-27 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
CN116143939A
(zh)
*
|
2017-11-24 |
2023-05-23 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多重活性蛋白
|
CN111518770B
(zh)
|
2017-12-19 |
2023-01-06 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
CN113603794B
(zh)
*
|
2018-01-11 |
2024-01-16 |
安源医药科技(上海)有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
CN110092835A
(zh)
*
|
2018-01-30 |
2019-08-06 |
上海惠盾生物技术有限公司 |
一种glp-1类似物-col3a1融合蛋白
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
WO2019190752A1
(en)
|
2018-03-30 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of glycoproteins
|
DK3774862T3
(da)
|
2018-04-05 |
2022-09-05 |
Sun Pharmaceutical Ind Ltd |
Nye GLP-1-analoger
|
CR20200510A
(es)
|
2018-04-09 |
2020-11-26 |
Amgen Inc |
Protreínas de fusión del factor de diferenciación de crecimiento 15
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
CN110964116A
(zh)
*
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
EA202191105A1
(ru)
*
|
2018-10-22 |
2021-08-03 |
Янссен Фармацевтика Нв |
Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
|
CA3121043A1
(en)
|
2018-12-03 |
2020-06-11 |
Antag Therapeutics Aps |
Modified gip peptide analogues
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
TW202024134A
(zh)
|
2018-12-21 |
2020-07-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
雙特異性蛋白
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
CN110151980B
(zh)
*
|
2019-06-30 |
2022-12-09 |
中国药科大学 |
Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
|
KR20220143037A
(ko)
|
2020-02-18 |
2022-10-24 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 이의 용도
|
AU2021224412A1
(en)
|
2020-02-22 |
2022-09-15 |
Jcr Pharmaceuticals Co., Ltd. |
Human transferrin receptor binding peptide
|
CN115925994B
(zh)
*
|
2020-09-30 |
2023-09-22 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
EP4317174A1
(en)
|
2021-03-22 |
2024-02-07 |
Peptiaid Inc |
Peptide and peptide-containing composition
|
TW202305012A
(zh)
|
2021-03-22 |
2023-02-01 |
日商肽夢想股份有限公司 |
c-Met 蛋白質結合肽複合物
|
CN113150172B
(zh)
*
|
2021-04-28 |
2023-09-22 |
中国药科大学 |
Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
|
CA3222510A1
(en)
|
2021-06-18 |
2022-12-22 |
Peptidream Inc. |
Ghr-binding pending peptide and composition comprising same
|
AU2022329794A1
(en)
|
2021-08-19 |
2024-02-22 |
Jcr Pharmaceuticals Co., Ltd. |
Human transferrin receptor–binding peptide
|
JPWO2023026994A1
(pl)
|
2021-08-21 |
2023-03-02 |
|
|
WO2023027125A1
(ja)
|
2021-08-24 |
2023-03-02 |
ペプチドリーム株式会社 |
ヒトトランスフェリンレセプター結合抗体-ペプチドコンジュゲート
|
AU2022355276A1
(en)
|
2021-09-30 |
2024-05-16 |
Peptidream Inc. |
Peptide
|
CN113801853B
(zh)
*
|
2021-11-19 |
2022-03-15 |
山东兴瑞生物科技有限公司 |
Exendin-4融合基因修饰的MSC及其应用
|
WO2023179796A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
|
CN116848243B
(zh)
*
|
2022-03-30 |
2024-03-19 |
北京质肽生物医药科技有限公司 |
多肽缀合物的液体药物组合物和其使用方法
|
CN114774496B
(zh)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高密度发酵制备glp-1类似物的方法
|